Phase 2
Systemic Sclerosis ILD
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Organization | University

Drug Details

CD34+ positively selected peripheral blood stem cells (PBSC) is a high-dose immunoablative therapy.

Study Purpose

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect. We also hypothesize that our mechanistic studies will yield biomarkers that may herald disease recurrence or progression following alterations in the recovery of immune cells in the skin and/or bronchial lavage or blood.

Find a Clinical Trial